Lifeboat Foundation

Cryotechnology has been used in treating lung cancer for many years, now it is emerging to have a new indication in diagnosing lung diseases. Cryoprobe transbronchial lung biopsy has been introduced into clinical practice as a new technique, providing a larger biopsy specimen, potentially improving the diagnostic yield of transbronchial biopsies in parenchymal lung diseases. Although recent small pilot studies suggest that cryotransbronchial lung biopsies are comparable to conventional transbronchial biopsies in terms of diagnostic yield and safety profile in lung transplant patients, cryoprobe transbronchial lung biopsy is still being evaluated and its role in clinical practice is not well defined. Cryotherapy has been proven as a safe and effective method to debulk endobronchial lesions, providing palliation for advanced central obstructive tumors. Its use and efficacy is also studied in direct cryosurgery and percutaneous application in lung cancer. Cryoprobes can also be used to extract foreign bodies from the airways by causing cryoadhesion. We aim to summarize the therapeutic and diagnostic application of cryotechnology in pulmonary diseases.

Ischemic stroke is a condition in which parts of the brain lose their blood supply, causing nerve damage. Once brain tissue suffers irreparable harm, the patient will experience irreversible disability or death, depending on the extent of neuronal loss. However, glial cells surrounding the neurons are activated by the injury and multiply. Now, scientists have found out how to insert genes into glial cells to convert them into neurons, thus filling in for some of the lost functioning cells to improve motor functions.

There are about 86 billion neurons in the brain, but billions of them can be lost with one moderate-sized stroke. About 800,000 new strokes occur each year in the US alone. The need is to regenerate new brain cells to replace the ones that die, at least partially. This is the only known way to restore motor functions that have been impaired or destroyed by a stroke or other brain injury.

Heartburn drug Zantac has been found to be contaminated with low levels of a cancer-linked chemical. This is the same contaminant that lead to multiple recalls of blood pressure drugs.

Mei Mei Hu vowed to never work with her mother, Chang Yi, but she knew this was bigger than the both of them.

Continue reading “A Mother-Daughter Duo Develops What Could Be The World’s First Alzheimer’s Vaccine” »

Today, we’re offering another talk from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In her talk, Morgan Levine of the Yale School of Medicine discussed epigenetic biomarkers in detail, discussing the ways in which co-methylation networks provide insight into senescent cells and other facets of biological age.

I’m excited to share my new article for The New York Times on the brave new world of #cyborg ability and coming #transhumanism sports:

I wonder whether the sporting industry might create some new competitions where — just like technology — performance-enhancing drugs are encouraged. Innovations like the new oxygen-infused injection, which might one day allow humans to hold their breath for 15 to 30 minutes, could allow competitive free divers to reach new depths, showing just how far the human body can go.

Critics will complain that the human body was not designed to compete using enhancements and that it violates the code given to us by the ancient Greeks and their first Olympics Games, where “arête,” or excellence and moral virtue, was cherished. As a longtime competitive athlete, I appreciate the sportsmanship angle; but I also think that in the 21st century we can develop both the drugs and the technology to see humans compete in new sporting events that are even more exciting than their predecessors.

Continue reading “The Brave New World of Sports” »

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Today, we’re releasing a talk from Dr. Doug Ethell, who announced his company’s efforts to combat Alzheimer’s disease, describing where and how this neurodegenerative disease starts and discussing his company’s work on developing therapies for the cribiform plate, which naturally clears amyloid-forming proteins from the brain before they aggregate.